{"id":2077642,"date":"2023-10-24T11:29:04","date_gmt":"2023-10-24T15:29:04","guid":{"rendered":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/rsv-vaccine-for-infants-in-limited-supply-cdc\/"},"modified":"2023-10-24T11:34:01","modified_gmt":"2023-10-24T15:34:01","slug":"rsv-vaccine-for-infants-in-limited-supply-cdc","status":"publish","type":"post","link":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/rsv-vaccine-for-infants-in-limited-supply-cdc\/","title":{"rendered":"Limited supply of RSV vaccine for infants, warns CDC."},"content":{"rendered":"<aside class=\"mashsb-container mashsb-main mashsb-stretched\"><div class=\"mashsb-box\"><div class=\"mashsb-count mash-medium\" style=\"&quot;\"><div class=\"counts mashsbcount\">18<\/div><span class=\"mashsb-sharetext\">SHARES<\/span><\/div><div class=\"mashsb-buttons\"><a class=\"mashicon-facebook mash-medium mash-nomargin mashsb-noshadow\" href=\"https:\/\/www.facebook.com\/sharer.php?u=https%3A%2F%2Fwww.conservativenewsdaily.net%2Fbreaking-news%2Frsv-vaccine-for-infants-in-limited-supply-cdc%2F\" target=\"_top\" rel=\"nofollow\"><span class=\"icon\"><\/span><span class=\"text\">Facebook<\/span><\/a><a class=\"mashicon-twitter mash-medium mash-nomargin mashsb-noshadow\" href=\"https:\/\/twitter.com\/intent\/tweet?text=&amp;url=https:\/\/www.conservativenewsdaily.net\/breaking-news\/?p=2077642&amp;via=ConservNewsDly\" target=\"_top\" rel=\"nofollow\"><span class=\"icon\"><\/span><span class=\"text\">Twitter<\/span><\/a><a class=\"mashicon-subscribe mash-medium mash-nomargin mashsb-noshadow\" href=\"#\" target=\"_top\" rel=\"nofollow\"><span class=\"icon\"><\/span><span class=\"text\">Subscribe<\/span><\/a><div class=\"onoffswitch2 mash-medium mashsb-noshadow\" style=\"display:none\"><\/div><\/div>\n            <\/div>\n                <div style=\"clear:both\"><\/div><\/aside>\n            <!-- Share buttons by mashshare.net - Version: 4.0.47--><blockquote>\n<h2>The CDC Alerts Clinicians About Short Supply of Monoclonal Antibody Treatment for RSV in \u200dInfants<\/h2>\n<p>The Centers for Disease Control and Prevention (CDC) issued \u2063a \u200dhealth advisory \u2063on Monday, notifying clinicians about\u200b the\u200c limited \u200cavailability of\u200d monoclonal\u2062 antibody \u2062treatment for <a href=\"https:\/\/www.conservativenewsdaily.net\/breaking-news\/the-fda-just-authorized-an-at-home-test-for-covid-19-rsv-and-the-flu\/\" title=\"The FDA Just Authorized an At-Home Test for COVID-19, RSV and the Flu\">respiratory syncytial virus<\/a> (RSV) in infants.\u200c With an increase in demand,\u200b the CDC recommends prioritizing the use of 100-milligram doses of the monoclonal antibody nirsevimab for infants under 6\u2063 months old and those with underlying\u200c conditions.<\/p>\n<div class=\"my-5\">\n<p>In its\u2062 health advisory,\u200c the \u200bCDC suggests reserving 50 milligram nirsevimab doses for\u200d infants weighing less than 11 \u2064pounds. Additionally, the use of nirsevimab\u200c should be suspended for infants \u200deligible for palivizumab, another monoclonal antibody for RSV. \u200cHowever, the CDC emphasizes that nirsevimab should still be offered to American\u2062 Indian and Alaska Native children aged \u200d8\u201319 months who are not eligible for palivizumab\u200c and live\u2063 in remote regions \u200bwhere accessing medical care for severe RSV is challenging.<\/p>\n<p>Nirsevimab, marketed as Beyfortus, is manufactured \u2064by AstraZeneca and marketed by \u200bSanofi. It was approved by \u200bthe Food and Drug Administration\u200d (FDA) in July to \u200bprevent RSV disease in \u2064infants. According to the CDC, Beyfortus has been proven to reduce the risk of hospitalizations and healthcare visits for RSV in infants by about 80 percent.<\/p>\n<p>Sanofi has acknowledged the unprecedented demand for Beyfortus and is working \u200bwith AstraZeneca to \u2064expedite additional supply and expand \u2062the\u2064 manufacturing network.<\/p>\n<\/p><\/div>\n<h2>Increase in\u200d RSV Cases<\/h2>\n<p>The CDC recently warned about a rise in RSV\u200c cases in certain parts\u2063 of the southeastern\u2063 United States, indicating a return to pre-pandemic seasonal trends. Historically, regional increases have preceded a national surge in RSV activity over the following months. From August 5 to August 19, RSV-related hospitalizations increased significantly, \u2064particularly among\u2064 infants under a year old.<\/p>\n<p>In response \u200dto\u2062 this surge, the CDC urges clinicians to\u2063 prepare for the upcoming RSV season by implementing\u2064 new \u200dprevention\u2064 options, including administering monoclonal antibody products and nirsevimab as \u2064a preventative treatment.<\/p>\n<div class=\"post-figure\">\n<figure style=\"width:600px\" class=\"alignnone\"><figcaption>A 1981 electron \u2062microscope image of a human respiratory syncytial virus (RSV). (Centers for Disease Control and Prevention via AP)<\/figcaption><\/figure>\n<\/p><\/div>\n<p>RSV is a virus that\u200d causes <a href=\"https:\/\/www.conservativenewsdaily.net\/breaking-news\/report-flu-has-virtually-disappeared-from-u-s\/\" title=\"Report: Flu Has \u2018Virtually Disappeared\u2019 From U.S.\">acute respiratory infection<\/a> in individuals of all age groups.\u200b While most\u2064 infants\u2063 and <a href=\"https:\/\/www.conservativenewsdaily.net\/breaking-news\/rsv-vaccine-for-infants-in-limited-supply-cdc\/\" title=\"Limited supply of RSV vaccine for infants, warns CDC.\">young children experience mild symptoms similar<\/a> to a cold, some infants, especially during their first infection, may \u2064develop more severe lower respiratory tract conditions such as pneumonia and bronchiolitis. RSV hospitalizes over\u200c 58,000 children under the \u2063age of 5 in the United \u2063States each year, with approximately 100 to 300 deaths in this age\u2062 group.<\/p>\n<p>RSV\u2062 is transmitted through close contact with infected individuals and typically spreads seasonally, starting\u200b in the fall and\u2062 peaking in the winter \u2062in most regions\u2063 of the United\u200d States.<\/p>\n<div class=\"my-5\">\n    <em>Katabella Roberts contributed to this report.<\/em>\n  <\/div>\n<\/blockquote>\n<p> <\/p>\n<h2> What is \u200cthe significance of the shortage of monoclonal antibody treatment for RSV in infants?<\/h2>\n<p><span>  Italization due to severe RSV by 70% in infants.<\/p>\n<p>The shortage of monoclonal \u200cantibody treatment for RSV in infants is concerning, especially considering the increased demand for these treatments. RSV\u200b is a \u2064common respiratory \u200dvirus that can cause\u2062 severe illness \u200cin infants, particularly\u200c those born prematurely or with underlying health conditions. It is important to prioritize the use\u2064 of available doses to ensure infants at the highest risk receive the necessary treatment.<\/p>\n<p>The CDC&#8217;s recommendation to \u200cprioritize the use of 100-milligram\u2064 doses of nirsevimab for infants under 6 months old and those with underlying conditions is based on the efficacy of this treatment in reducing the risk of hospitalization. By reserving 50 milligram doses for\u2063 infants weighing less than 11 pounds, healthcare providers can ensure the appropriate dosage is given to this specific population.<\/p>\n<p>It is also crucial to suspend the use of nirsevimab for infants \u200beligible for palivizumab, another monoclonal \u2064antibody \u2062for RSV. This allows for the optimal use of \u200cavailable treatments and prevents potential overdose or adverse reactions. However, the CDC acknowledges the unique circumstances of American Indian and Alaska Native children aged 8-19 months living in remote regions where access to medical care for severe RSV is challenging. In these cases, nirsevimab should still be offered as an alternative preventive measure.<\/p>\n<p>The approval of nirsevimab by the \u200dFDA in July was a significant \u200ddevelopment in the prevention \u2062of RSV disease in infants. It \u2064provided healthcare providers \u2063with an additional tool to protect vulnerable infants from severe illness.\u2063 The shortage of this treatment \u200braises \u2063concerns about the potential impact on infant health \u200dand the ability to adequately respond to the rising cases of RSV.<\/p>\n<p>Healthcare organizations, \u2063manufacturers, and regulatory bodies should collaborate to address the shortage of monoclonal \u2064antibody treatment for RSV. This may involve \u2062increasing \u200cproduction capacity, exploring alternative treatment options, and implementing measures to ensure equitable \u2064distribution.\u200d It is crucial to\u2064 prioritize the health and well-being of infants\u2062 by ensuring access to life-saving treatments.<\/p>\n<p>In conclusion, the CDC&#8217;s alert regarding the limited availability of monoclonal antibody treatment for RSV in infants highlights \u200dthe importance \u2062of careful \u2064allocation and prioritization. Healthcare providers must adhere to the CDC&#8217;s recommendations to ensure that infants at the highest risk receive the necessary treatment. Efforts should be\u2064 made to address the shortage\u200d and ensure the availability of these life-saving treatments for all infants in need.<\/p>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"<p>The CDC has warned clinicians of a shortage of monoclonal antibody treatment for RSV in infants. Due to increased demand, they recommend prioritizing available 100mg doses of nirsevimab for infants under 6 months old. Health advisory issued.<\/p>\n","protected":false},"author":299,"featured_media":2077643,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_mo_disable_npp":"","fifu_image_url":"https:\/\/cndimages.nyc3.digitaloceanspaces.com\/breaking-news\/wp-content\/uploads\/2021\/01\/IMG_2758-scaled-1.jpg","fifu_image_alt":"","footnotes":""},"categories":[543],"tags":[],"class_list":["post-2077642","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-the-epoch-times"],"fifu_image_url":"https:\/\/cndimages.nyc3.digitaloceanspaces.com\/breaking-news\/wp-content\/uploads\/2021\/01\/IMG_2758-scaled-1.jpg","_links":{"self":[{"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/posts\/2077642","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/users\/299"}],"replies":[{"embeddable":true,"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/comments?post=2077642"}],"version-history":[{"count":0,"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/posts\/2077642\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/media\/2077643"}],"wp:attachment":[{"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/media?parent=2077642"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/categories?post=2077642"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/tags?post=2077642"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}